Cytoprotection by melatonin: The metabolic syndrome as an example

Abstract: As for metabolic syndrome (MS), several risk factors for cardiovascular disease are known, including elevated blood pressure, hyperinsulinemia, glucose intolerance, and dyslipidemia. We hereby discussed the special role that the chronobiotic/cytoprotective properties of melatonin may have...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cardinali, Daniel Pedro, Vigo, Daniel Eduardo
Formato: Parte de libro
Lenguaje:Español
Publicado: Springer 2022
Materias:
MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/15402
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-15402
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Español
topic MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
spellingShingle MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
Cytoprotection by melatonin: The metabolic syndrome as an example
topic_facet MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
description Abstract: As for metabolic syndrome (MS), several risk factors for cardiovascular disease are known, including elevated blood pressure, hyperinsulinemia, glucose intolerance, and dyslipidemia. We hereby discussed the special role that the chronobiotic/cytoprotective properties of melatonin may have in prevention and treatment of MS. Melatonin levels are consistently reduced in MS. The therapeutic potential of melatonin includes improvement of sleep efficiency and antioxidant and anti-inflammatory properties that derive partly from its role as a metabolic regulator and mitochondrial protector. This article analyzes the actions of melatonin that are relevant to the attenuation of inflammatory responses in MS and how melatonin is effective to curtail MS in animal models of hyperadiposity and ischemic and nonischemic heart failure. The clinical data supporting the therapeutical use of melatonin in human MS are also reviewed. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e., in the 40–100 mg/day range). The off-label use of melatonin is finally discussed.
format Parte de libro
author Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
author_facet Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
author_sort Cardinali, Daniel Pedro
title Cytoprotection by melatonin: The metabolic syndrome as an example
title_short Cytoprotection by melatonin: The metabolic syndrome as an example
title_full Cytoprotection by melatonin: The metabolic syndrome as an example
title_fullStr Cytoprotection by melatonin: The metabolic syndrome as an example
title_full_unstemmed Cytoprotection by melatonin: The metabolic syndrome as an example
title_sort cytoprotection by melatonin: the metabolic syndrome as an example
publisher Springer
publishDate 2022
url https://repositorio.uca.edu.ar/handle/123456789/15402
work_keys_str_mv AT cardinalidanielpedro cytoprotectionbymelatoninthemetabolicsyndromeasanexample
AT vigodanieleduardo cytoprotectionbymelatoninthemetabolicsyndromeasanexample
bdutipo_str Repositorios
_version_ 1764820523747901441

Ejemplares similares